Literature DB >> 15163261

Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.

Suellen M Curkendall1, Jingping Mo, Dale B Glasser, Mary Rose Stang, Judith K Jones.   

Abstract

BACKGROUND: Studies have shown that patients with schizophrenia have higher rates of cardiovascular disease and mortality compared with the general population. However, population-based data on the prevalence, incidence, and mortality of cardiovascular disease are needed.
METHOD: In this retrospective cohort study, the Saskatchewan Health databases were searched for all patients diagnosed with schizophrenia (ICD-9 code 295) in 1994 or 1995. 3022 subjects were identified. For each subject, 4 age- and sex-matched comparison individuals were selected randomly among residents of the province who had no diagnosis of schizophrenia or any other mental disorders and who received no prescriptions for antipsychotic medications. Prevalence of cardiovascular morbidity during 1994 and 1995 and incidence of cardiovascular morbidity and mortality during the follow-up period of January 1996 through March 1999 were analyzed.
RESULTS: Concerning prevalence of morbidity in schizophrenia patients, significantly increased risk-adjusted odds ratios were as follows: arrhythmia, 1.5 (95% CI = 1.2 to 1.8); syncope, 4.0 (95% CI = 2.0 to 7.9); heart failure, 1.7 (95% CI = 1.4 to 2.2); stroke, 2.1 (95% CI = 1.6 to 2.7); transient cerebral ischemia, 2.6 (95% CI = 1.7 to 3.7); and diabetes, 2.1 (95% CI = 1.8 to 2.4). Odds of acute myocardial infarction, ischemic heart disease, and ventricular arrhythmias were not significantly different from those for the comparison group. Concerning incidence of morbidity and mortality in the patients, adjusted relative risk was significantly increased for ventricular arrhythmia, 2.3 (95% CI = 1.2 to 4.3); heart failure, 1.6 (95% CI = 1.2 to 2.0); stroke, 1.5 (95% CI = 1.2 to 2.0); diabetes, 1.8 (95% CI = 1.2 to 2.6); all-cause mortality, 2.8 (95% CI = 2.3 to 3.4); and cardiovascular mortality, 2.2 (95% CI = 1.7 to 2.8).
CONCLUSIONS: Persons with schizophrenia appear to be at greater risk for cardiovascular morbidity and mortality than those in the general population.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163261     DOI: 10.4088/jcp.v65n0519

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  47 in total

1.  Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States.

Authors:  Charles E Leonard; Cristin P Freeman; Craig W Newcomb; Warren B Bilker; Stephen E Kimmel; Brian L Strom; Sean Hennessy
Journal:  J Clin Exp Cardiolog       Date:  2013

Review 2.  The art and science of risk management: a US research-based industry perspective.

Authors:  Janice K Bush; Wanju S Dai; Gretchen S Dieck; Linda S Hostelley; Thomas Hassall
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

3.  Prevalence and associations of the metabolic syndrome among patients prescribed clozapine.

Authors:  M Ahmed; I Hussain; S M O'Brien; B Dineen; D Griffin; C McDonald
Journal:  Ir J Med Sci       Date:  2008-05-07       Impact factor: 1.568

Review 4.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

5.  Quality of care for heart failure among disabled Medicaid recipients with and without severe mental illness.

Authors:  Saul Blecker; Yiyi Zhang; Daniel E Ford; Eliseo Guallar; Susan Dosreis; Donald M Steinwachs; Lisa B Dixon; Gail L Daumit
Journal:  Gen Hosp Psychiatry       Date:  2010-03-16       Impact factor: 3.238

Review 6.  Preparing for safety issues following drug approval: pre-approval risk management considerations.

Authors:  Gretchen S Dieck; Robert G Sharrar
Journal:  Ther Adv Drug Saf       Date:  2013-10

7.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 8.  Lipid effects of psychiatric medications.

Authors:  Junzo Watanabe; Yutaro Suzuki; Toshiyuki Someya
Journal:  Curr Atheroscler Rep       Date:  2013-01       Impact factor: 5.113

9.  Peer Supports for Tobacco Cessation for Adults with Serious Mental Illness: A Review of the Literature.

Authors:  Colleen E McKay; Faith Dickerson
Journal:  J Dual Diagn       Date:  2012-05-11

10.  Mental disorders, quality of care, and outcomes among older patients hospitalized with heart failure: an analysis of the national heart failure project.

Authors:  Saif S Rathore; Yongfei Wang; Benjamin G Druss; Frederick A Masoudi; Harlan M Krumholz
Journal:  Arch Gen Psychiatry       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.